These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation. Patel MS; Kohn R; Kratz JR; Shah JA; Markmann JF; Vagefi PA J Am Coll Surg; 2015 Jun; 220(6):1001-7. PubMed ID: 25868408 [TBL] [Abstract][Full Text] [Related]
3. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy. Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605 [TBL] [Abstract][Full Text] [Related]
4. History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist. Kotwani P; Saxena V; Dodge JL; Roberts J; Yao F; Hameed B Transplantation; 2018 May; 102(5):794-802. PubMed ID: 29319619 [TBL] [Abstract][Full Text] [Related]
5. The impact of marijuana use on liver transplant recipients: A 900 patient single center experience. Guorgui J; Ito T; Markovic D; Aziz A; Younan S; Severance A; Lu M; Lee J; DiNorcia J; Agopian VG; Farmer DG; Busuttil RW; Kaldas FM Clin Transplant; 2021 Apr; 35(4):e14215. PubMed ID: 33406299 [TBL] [Abstract][Full Text] [Related]
6. MELD EXCEPTION POINTS PROVIDE AN ENOURMOUS ADVANTAGE FOR RECEIVING A LIVER TRANSPLANT IN BRAZIL. Arruda S; Chedid MF; Jacinto MM; Álvares-DA-Silva MR Arq Gastroenterol; 2020; 57(3):254-261. PubMed ID: 32935744 [TBL] [Abstract][Full Text] [Related]
7. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma. Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270 [TBL] [Abstract][Full Text] [Related]
10. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. Goldaracena N; Gorgen A; Doyle A; Hansen BE; Tomiyama K; Zhang W; Ghanekar A; Lilly L; Cattral M; Galvin Z; Selzner M; Bhat M; Selzner N; McGilvray I; Greig PD; Grant DR; Sapisochin G J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009 [TBL] [Abstract][Full Text] [Related]
11. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Cullaro G; Rubin JB; Mehta N; Lai JC Liver Transpl; 2020 Mar; 26(3):349-358. PubMed ID: 31610089 [TBL] [Abstract][Full Text] [Related]
12. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222 [TBL] [Abstract][Full Text] [Related]
13. Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator. Díaz LA; Norero B; Lara B; Robles C; Elgueta S; Humeres R; Poniachik J; Silva G; Wolff R; Innocenti F; Rojas JL; Zapata R; Hunter B; Álvarez S; Cancino A; Ibarra J; Rius M; González S; Calabrán L; Pérez RM Ann Hepatol; 2019; 18(2):325-330. PubMed ID: 31010794 [TBL] [Abstract][Full Text] [Related]
14. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U; J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Sayiner M; Stepanova M; De Avila L; Golabi P; Racila A; Younossi ZM Dig Dis Sci; 2020 Feb; 65(2):416-422. PubMed ID: 31451982 [TBL] [Abstract][Full Text] [Related]
17. Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis. Meyerovich G; Goykhman Y; Nakache R; Nachmany I; Lahat G; Shibolet O; Menachem Y; Katchman H; Wolf I; Geva R; Klausner JM; Lubezky N Transplant Proc; 2019; 51(6):1867-1873. PubMed ID: 31399171 [TBL] [Abstract][Full Text] [Related]
18. [Analysis of the organ allocation system for liver transplantation in Chile]. Wolff R; Díaz LA; Norero B; Urzúa Á; Mezzano G; Humeres R; Innocenti F; Castro L; Pavez C; Derosas C; Elgueta S Rev Med Chil; 2020 Nov; 148(11):1541-1549. PubMed ID: 33844759 [TBL] [Abstract][Full Text] [Related]
19. Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma. Croome KP; Lee DD; Harnois D; Taner CB PLoS One; 2017; 12(1):e0170673. PubMed ID: 28122003 [TBL] [Abstract][Full Text] [Related]
20. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]